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Hospital, Falls Church, VA, United StatesSee Article, pages 905–912It is estimated that approximately 1 billion people around the
world may have Non-Alcoholic Fatty Liver Disease (NAFLD) with
a prevalence of 20–30% in Western countries [1–3]. Obesity is
both the most common predictor of NAFLD and the most rapidly
growing health concern in the world [4]. The growing number of
people, of all ages, who currently have NAFLD and the estimates
of those that will develop this condition based on the projected
rates of obesity, urgently necessitates numerous lines of research
focusing on the diagnosis and effective treatment of NAFLD.
Since NAFLD is so intricately correlated with insulin resistance
and obesity, a natural and surprisingly understudied area of
NAFLD research is the study of the changes in the lipid composi-
tion of biological ﬂuids and relevant tissues through the explora-
tion of a broad ﬁeld commonly known as: lipidomics. It is evident
that the changes in the lipid proﬁles within the liver, the adipose
tissue and the plasma, accompany NAFLD, however, the contribu-
tion of these changes to the pathogenesis of this disease remain
enigmatic [5]. In the current paper titled ‘‘Circulating phospho-
lipid proﬁling identiﬁes portal contribution to NASH signature
in obesity,’’ Anjani and colleagues used mass spectrometry-based
lipidomic analysis to dissect this so-called Non-Alcoholic
Steatohepatitis (NASH) ‘‘signature’’ in a cohort of 46 morbidly
obese women. The study simultaneously proﬁled several typesJournal of Hepatology 20
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Open access under CC BY-NC-ND license.of samples, including the venous blood specimens collected
before and 12 months post bariatric surgery and quantiﬁed the
lipid efﬂux in portal blood and adipose tissue at the time of
surgery. A total of 9 structural classes and 150 species of lipids
were analyzed in the hope to distinguish the subspecies of the
lipids that correlate most closely with liver disease status.
In the systemic blood specimens of NASH subjects as com-
pared to that of non-NASH subjects, the authors reported an
increase in the concentration of a variety of classes of lipids.
Interestingly, in patients who achieved weight loss 12 months
after bariatric surgery, the levels of liver enzymes normalized
along with a number of lipid species, however, a majority of
glycerophosphoglycerols (PG) and ceramide (Cer) species contin-
ued to be elevated. Further analysis of the lipids isolated from the
hepatic portal system indicated a minimal variance from those
seen in the systemic circulation, with the exception of PG
and glycerophosphoethanolamines (PE) classes which were
substantially elevated in the NASH cohort. Notably, when the
authors assessed the involvement of visceral adipose tissue to
this circulating lipid proﬁle by measuring adipose tissue lipid
efﬂux ex vivo, only minor differences were detected between
the NASH and the non-NASH cohorts.
Most interestingly, a Bayesiannetwork analysis of the lipid pro-
ﬁles fromthehepatic portal system, a knownconduit formolecules
from the visceral organs to the liver, revealed a high correlation
between glycerophosphocholines (PC) (40:4) and NASH, while
sphingomyelins (SM) (42:3) and a short chain (C14) Cer were
decreased in the portal circulation of NASH subjects. Heat map
visualization also showed NASH-speciﬁc alterations in lipid
proﬁles of the hepatic portal circulation. Notably, the best NASH
signature the authors could obtain was by integrating clinical
and lipidomic data, both portal and systemic, where all lipids
and clinical parameters were given equalweight. The authors con-
cluded that visceral adipose contributing to overall lipidome was
secondary to that of other sources of the drainage into the hepatic
portal system, for example, the gut. While this is by no means a
novel suggestion in the ﬁeld of NASH [5–7], the exact mechanism
of this contribution has yet to be demonstrated.15 vol. 62 j 761–762
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It is interesting to note that from a histological perspective
both PE and PC classes of lipids have been shown to be decreased
in liver tumors as compared to normal tissue [8]. Moreover, in
liver regeneration following hepatic resection, the decrease in
the levels of both PE and PC was observed [9], which may also
explain the disappearance of hepatic triacylglycerol (TAG) in
the histopathological progression of NAFLD from steatosis, to
early ﬁbrosis and then to cirrhosis. However, much less is known
about the circulating species of these lipids and their direct
contribution to NAFLD pathogenesis and progression. Perhaps
more mechanistically relevant to NAFLD, Gugliucci et al. were
able to demonstrate that low-density lipoprotein (LDL) glycation
is a predisposing event to subsequent oxidative modiﬁcation.
Most interestingly, LDL and very-low-density lipoprotein (VLDL)
fractions of diabetic patients are much more susceptible to
oxidation [10]. In turn, lipid oxidation has been shown to increase
the uptake of LDL particles by macrophages [11], with the glu-
cosylated PE being the major LDL lipid glycation products [12].
From a more global perspective, one may assume that an increase
in BMI leads to a larger inﬂux of nonesteriﬁed fatty acids (NEFAs)
to the liver, thus, causing elevation of their levels in the portal
blood of NASH subjects, reﬂecting a compensatory feedback
against oxidative stress [13]. Following this logic, with more
progression along the path to steatosis, lower levels of PE and
PG along with higher Cer and SM species should be observed as
the balance shifts towards hepatotoxic lipid species. Hence, this
study of Anjani and colleagues opens a Pandora’s box of possible
interpretations.
Nevertheless, this current study takes an important step
towards understanding some of the key players in the mecha-
nisms triggering and propagating NASH in obese women. It is
important to mention that the relatively small sample size limits
the generalizability of these ﬁndings. Nevertheless, the in-depth
lipidomic assessment provides some intriguing data about the
pathogenesis of NAFLD spectrum in obese individuals. Future
studies need to delve deeper into lipidomics, in larger cohorts
of both genders, properly controlled for medications, especially
lipid-lowering agents that may affect the outcomes [14,15].
Anjani et al. have taken an important step towards unraveling
the tangled threads of the obesity and NASH axis that warrant
more pathogenetic insights into metabolic syndrome and associ-
ated conditions, which are rapidly becoming the largest health
burden on the Western world health care system.Conﬂict of interest
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